PATENT CLAIM ANALYSIS

Application Number: 16320949
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "235500"]

Abstract:
The present invention relates to the combination of histamine-3 receptor inverse agonist and acetylcholinesterase inhibitor. Also, the present invention provides histamine-3 receptor (H 3 R) inverse agonist, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitor and their use in the treatment of cognitive disorders. The present invention further provides the pharmaceutical composition containing the said combination.

Claim (Index 1):
A combination comprising a histamine-3 receptor inverse agonist and an acetylcholinesterase inhibitor; wherein the histamine-3 receptor inverse agonist is selected from the group consisting of:\n N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; N-[4-(1-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; and N-[4-(1-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 99.0
- Lexical Diversity: 1.65909
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15211638', '15084712', '14021033', '14802036', '15194947']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.755700698721092
- 35 USC 102 Novelty (BERT): 0.5293114883915077
- Combined Prediction Score: 0.7330617776881335
- Mean Citation Score: 343.47358
- Max Citation Score: 354.63742
- Similarity Product: 244.5807272515237

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test